Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema:

Global & Regional Health Technology Assessment

FahdQuhill¹ 

关键词: Cost saving;    Diabetic retinopathy;    Fluocinolone acetonide;    Intravitreal injections;    Macular oedema;    Ranibizumab;   

DOI  :  10.5301/grhta.5000268

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

A cost analysis model was developed to evaluate the 3-year cost of treating vision impairment associated with chronic diabetic macular oedema (DMO) with either a single fluocinolone acetonide (FAc) implant or with 14 ranibizumab injections in the National Health Service (NHS) in England. The model accounts for the overall direct cost of treatment in both pseudophakic and phakic eyes including the cost of the drugs, the cost of administering the drugs, the cost of monitoring the patient, the cost of additional interventions required, and the cost of managing adverse events.

【 授权许可】

CC BY